LionTCR, a clinical-stage biotechnology company pioneering T-cell receptor (TCR)-based therapies, today announced that it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate phase1b/2 clinical trials for its proprietary TCR-T cell therapy, LioCyx-M004, in patients with chronic hepatitis B (CHB). This approval represents the third major regulatory […]

LionTCR, a clinical-stage biotechnology company pioneering T-cell receptor (TCR)-based therapies, today announced that it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate phase1b/2 clinical trials for its proprietary TCR-T cell therapy, LioCyx-M004, in patients with chronic hepatitis B (CHB). This approval represents the third major regulatory

NEW YORK, NY / ACCESS Newswire / September 14, 2025 / If you suffered a loss on your KinderCare Learning Companies, Inc. (NYSE:KLC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kindercare-learning-companies-inc-lawsuit-submission-form?prid=167194&wire=1&utm_campaign=20 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com

NEW YORK, NY / ACCESS Newswire / September 14, 2025 / If you suffered a loss on your Lantheus Holdings, Inc. (NASDAQ:LNTH) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/lantheus-holdings-inc-lawsuit-submission-form-2?prid=167195&wire=1&utm_campaign=28 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

Armor Health (ArmorHealthcare.com), today announced it's new partnership with Antidote-AI (Antidote-AI.com) as their correctional healthcare technology partner to provide Armor with their powerful AI clinical tools, embedded in Armor's Insights Analytics technology platform. https://mma.prnewswire.com/media/2764221/Armor_Health_RGB_Logo.jpg Powered by Antidote's AI solution, Armor's Insights Analytics will tie in objective measures and integrate objective scoring with assessments to provide

NEW YORK, NY / ACCESS Newswire / September 14, 2025 / If you suffered a loss on your Fly-E Group, Inc. (NASDAQ:FLYE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/fly-e-group-inc-lawsuit-submission-form?prid=167193&wire=1&utm_campaign=18 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / September 14, 2025 / If you suffered a loss on your Charter Communications, Inc. (NASDAQ:CHTR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/charter-communications-inc-lawsuit-submission-form?prid=167192&wire=1&utm_campaign=2 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / September 14, 2025 / If you suffered a loss on your Lockheed Martin Corporation (NYSE:LMT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/lockheed-martin-corporation-lawsuit-submission-form?prid=167190&wire=1&utm_campaign=31 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / September 14, 2025 / If you suffered a loss on your Alto Neuroscience, Inc. (NYSE:ANRO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/alto-neuroscience-inc-lawsuit-submission-form?prid=167191&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / September 14, 2025 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form-2?prid=167189&wire=1&utm_campaign=6 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call